Compare Sherwin-Williams Company (The) Common Stock (SHW) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sherwin-Williams Company (The) Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Sherwin-Williams Company (The) Common Stock trades at $327.77 (market cap $78.78B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Sherwin-Williams Company (The) Common Stock is far larger — about 10.7× Spyre Therapeutics Inc. Common Stock's market cap, and Sherwin-Williams Company (The) Common Stock pays a 0.99% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals.
| SHW | SYRE | |
|---|---|---|
Market Cap | $78.78B | $7.35B |
Volume | 1,403,311 | 1,624,631 |
Sector | Basic Materials | Health |
52-Week High | $372.60 | $108.92 |
52-Week Low | $293.00 | $22.18 |
Enterprise Value | $92.71B | $6.35B |
Dividend Yield | 0.99% | — |
Typical Hold Time | — | 0 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sherwin-Williams (SHW) trades at $324.10, up 1.21% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows neutral technical signals but maintains robust fundamentals with 65.12% ROE and expanding manufacturing capacity. Recent facility expansions in Statesville enhance production capabilities, positioning the company for continued market share gains.
Outlook remains positive with analyst consensus at Buy (57.9%) and $383.64 price target, though high valuation multiples (P/E 29.9) and competitive pressures present risks. Earnings growth and strategic investments support upside potential, while margin compression and economic sensitivity warrant monitoring.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Sherwin-Williams Company (The) Common Stock
The Sherwin-Williams Company manufactures, develops, and distributes paints, coatings, and related products through three segments: Paint Stores Group, operating more than 4,900 company-owned stores selling Sherwin-Williams-branded products; Consumer Brands Group, selling brands such as Valspar, Dutch Boy, Krylon, and Minwax through mass merchandisers and home centers; and Performance Coatings Group, supplying industrial, construction, and transportation coatings in more than 120 countries.
Read more on SHW →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
